BRCA1 and breast carcinoma: These therapeutic agents could also be effective for sporadic breast cancers with abnormalities in the BRCA genes, which is, as shown here, a considerably larger proportion of all breast cancer patients than germline BRCA1 or BRCA2 mutation carriers.